Skip to main content
Top
Published in: Health and Quality of Life Outcomes 1/2024

Open Access 01-12-2024 | Huntington's Disease | Review

Health state utility estimates for value assessments of novel treatments in Huntington’s disease: a systematic literature review

Authors: Ruta Sawant, Kyle Paret, Jennifer Petrillo, Aaron Koenig, Sorrel Wolowacz, Naoko Ronquest, Hugh Rickards

Published in: Health and Quality of Life Outcomes | Issue 1/2024

Login to get access

Abstract

Background

Huntington’s disease (HD) is a progressive neurodegenerative disease with a devastating impact on patients and their families. Quantifying how treatments affect patient outcomes is critical for informing reimbursement decisions. Many countries mandate a formal value assessment in which the treatment benefit is measured as quality-adjusted life-years, calculated with the use of utility estimates that reflect respondents’ preferences for health states.

Objective

To summarize published health state utility data in HD and identify gaps and uncertainties in the data available that could be used to inform value assessments.

Methods

We conducted a systematic literature review of studies that used preference-based instruments (e.g., EQ-5D and SF-6D) to estimate utility values for people with HD. The studies were published between January 2012 and December 2022.

Results

Of 383 articles screened, 16 articles reported utility values estimated in 11 distinct studies. The utility measure most frequently reported was EQ-5D (9/11 studies). Two studies reported SF-6D data; one used time trade-off methods to value health state descriptions (vignettes). Although utility scores generally worsened to a lower value with increased HD severity, the estimates varied considerably across studies. The EQ-5D index range was 0.89 − 0.72 for mild/prodromal HD and 0.71 − 0.37 for severe/late-stage disease.

Conclusions

This study uncovered high variability in published utility estimates, indicating substantial uncertainty in existing data. Further research is needed to better understand preferences and valuation across all stages and domains of HD symptoms and the degree to which generic utility measures capture the impact of cognitive changes on quality of life.
Appendix
Available only for authorised users
Literature
2.
go back to reference Medina A, Mahjoub Y, Shaver L, Pringsheim T. Prevalence and incidence of Huntington’s disease: an updated systematic review and meta-analysis. Mov Disord. 2022. Medina A, Mahjoub Y, Shaver L, Pringsheim T. Prevalence and incidence of Huntington’s disease: an updated systematic review and meta-analysis. Mov Disord. 2022.
3.
go back to reference Domaradzki J. The impact of Huntington disease on family carers: a literature overview. Psychiatr Pol. 2015;49(5):931–44.CrossRefPubMed Domaradzki J. The impact of Huntington disease on family carers: a literature overview. Psychiatr Pol. 2015;49(5):931–44.CrossRefPubMed
4.
go back to reference Furby H, Siadimas A, Rutten-Jacobs L, Rodrigues FB, Wild EJ. Natural history and burden of Huntington’s disease in the UK: a population‐based cohort study. Eur J Neurol. 2022;29(8):2249–57.CrossRefPubMedPubMedCentral Furby H, Siadimas A, Rutten-Jacobs L, Rodrigues FB, Wild EJ. Natural history and burden of Huntington’s disease in the UK: a population‐based cohort study. Eur J Neurol. 2022;29(8):2249–57.CrossRefPubMedPubMedCentral
5.
go back to reference Bayen E, de Langavant LC, Youssov K, Bachoud-Lévi A-C. Informal care in Huntington’s disease: assessment of objective-subjective burden and its associated risk and protective factors. Ann Phys Rehabil Med. 2023;66(4):101703.CrossRefPubMed Bayen E, de Langavant LC, Youssov K, Bachoud-Lévi A-C. Informal care in Huntington’s disease: assessment of objective-subjective burden and its associated risk and protective factors. Ann Phys Rehabil Med. 2023;66(4):101703.CrossRefPubMed
6.
go back to reference Ferguson MW, Kennedy CJ, Palpagama TH, Waldvogel HJ, Faull RL, Kwakowsky A. Current and possible future therapeutic options for Huntington’s disease. J Cent Nerv Syst Disease. 2022;14:11795735221092517. Ferguson MW, Kennedy CJ, Palpagama TH, Waldvogel HJ, Faull RL, Kwakowsky A. Current and possible future therapeutic options for Huntington’s disease. J Cent Nerv Syst Disease. 2022;14:11795735221092517.
7.
go back to reference Drummond MF, Hartgers-Gubbels ES, Chambers M. Value Insider season 1 episode 1: the importance of payers and HTA: how did we end up here?(introduction to value)[podcast]. Int J Gen Med. 2022:7487–92. Drummond MF, Hartgers-Gubbels ES, Chambers M. Value Insider season 1 episode 1: the importance of payers and HTA: how did we end up here?(introduction to value)[podcast]. Int J Gen Med. 2022:7487–92.
8.
go back to reference Rutten-van Mölken, Maureen PMH, Hartgers-Gubbels E, Sophia CM. Value Insider season 1 episode 4: how are costs measured, and how are CEAs constructed and used?(CEA)[podcast]. Int J Gen Med. 2022:8055–61. Rutten-van Mölken, Maureen PMH, Hartgers-Gubbels E, Sophia CM. Value Insider season 1 episode 4: how are costs measured, and how are CEAs constructed and used?(CEA)[podcast]. Int J Gen Med. 2022:8055–61.
9.
go back to reference Devlin NJ, Hartgers-Gubbels ES, Chambers M. Value Insider season 1 episode 2: how to measure quality of life and utility?(QoL)[podcast]. Int J Gen Med. 2022:7773–9. Devlin NJ, Hartgers-Gubbels ES, Chambers M. Value Insider season 1 episode 2: how to measure quality of life and utility?(QoL)[podcast]. Int J Gen Med. 2022:7773–9.
10.
go back to reference van Lonkhuizen PJ, Frank W, Heemskerk A-W et al. Quality of life, health-related quality of life, and associated factors in Huntington’s disease: a systematic review. J Neurol. 2023:1–22. van Lonkhuizen PJ, Frank W, Heemskerk A-W et al. Quality of life, health-related quality of life, and associated factors in Huntington’s disease: a systematic review. J Neurol. 2023:1–22.
11.
go back to reference Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Int J Surg. 2021;88:105906.CrossRefPubMed Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Int J Surg. 2021;88:105906.CrossRefPubMed
12.
go back to reference Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535.CrossRefPubMedPubMedCentral Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535.CrossRefPubMedPubMedCentral
13.
go back to reference Carlozzi NE, Kratz AL, Downing NR, et al. Validity of the 12-item World Health Organization disability assessment schedule 2.0 (WHODAS 2.0) in individuals with Huntington disease (HD). Qual Life Res. 2015;24:1963–71.CrossRefPubMedPubMedCentral Carlozzi NE, Kratz AL, Downing NR, et al. Validity of the 12-item World Health Organization disability assessment schedule 2.0 (WHODAS 2.0) in individuals with Huntington disease (HD). Qual Life Res. 2015;24:1963–71.CrossRefPubMedPubMedCentral
14.
go back to reference Carlozzi NE, Hahn EA, Goodnight SM, et al. Patient-reported outcome measures in Huntington disease: quality of life in neurological disorders (Neuro-QoL) social functioning measures. Psychol Assess. 2018;30(4):450.CrossRefPubMed Carlozzi NE, Hahn EA, Goodnight SM, et al. Patient-reported outcome measures in Huntington disease: quality of life in neurological disorders (Neuro-QoL) social functioning measures. Psychol Assess. 2018;30(4):450.CrossRefPubMed
15.
go back to reference Carlozzi NE, Goodnight S, Kratz AL, et al. Validation of Neuro-QoL and PROMIS mental health patient reported outcome measures in persons with Huntington disease. J Huntingtons Dis. 2019;8(4):467–82.CrossRefPubMedPubMedCentral Carlozzi NE, Goodnight S, Kratz AL, et al. Validation of Neuro-QoL and PROMIS mental health patient reported outcome measures in persons with Huntington disease. J Huntingtons Dis. 2019;8(4):467–82.CrossRefPubMedPubMedCentral
16.
go back to reference Carlozzi NE, Schilling S, Lai J-S, et al. HDQLIFE: development and assessment of health-related quality of life in Huntington disease (HD). Qual Life Res. 2016;25:2441–55.CrossRefPubMedPubMedCentral Carlozzi NE, Schilling S, Lai J-S, et al. HDQLIFE: development and assessment of health-related quality of life in Huntington disease (HD). Qual Life Res. 2016;25:2441–55.CrossRefPubMedPubMedCentral
17.
go back to reference Claassen DO, Ayyagari R, Goldschmidt D, Zhou M, Leo S, Ribalov R. Defining utility values for chorea health states in patients with Huntington’s disease. Adv Ther. 2022;39(4):1784–93.CrossRefPubMedPubMedCentral Claassen DO, Ayyagari R, Goldschmidt D, Zhou M, Leo S, Ribalov R. Defining utility values for chorea health states in patients with Huntington’s disease. Adv Ther. 2022;39(4):1784–93.CrossRefPubMedPubMedCentral
18.
go back to reference Rodriguez Santana I, Frank S, Doherty M, et al. Humanistic burden of Huntington Disease: evidence from the Huntington disease burden of illness study. Neurol Clin Pract. 2022;12(6):e172–80.CrossRefPubMedPubMedCentral Rodriguez Santana I, Frank S, Doherty M, et al. Humanistic burden of Huntington Disease: evidence from the Huntington disease burden of illness study. Neurol Clin Pract. 2022;12(6):e172–80.CrossRefPubMedPubMedCentral
19.
go back to reference Dorey J, Clay E, Khemiri A, Belhadj A, Cubillo PT, Toumi M. The quality of life of Spanish patients with Huntington’s disease measured with H-QoL-I and EQ-5D. J Mark Access Health Policy. 2016;4(1):27356.CrossRef Dorey J, Clay E, Khemiri A, Belhadj A, Cubillo PT, Toumi M. The quality of life of Spanish patients with Huntington’s disease measured with H-QoL-I and EQ-5D. J Mark Access Health Policy. 2016;4(1):27356.CrossRef
20.
go back to reference Quinn L, Hamana K, Kelson M, et al. A randomized, controlled trial of a multi-modal exercise intervention in Huntington’s disease. Parkinsonism Relat Disord. 2016;31:46–52.CrossRefPubMed Quinn L, Hamana K, Kelson M, et al. A randomized, controlled trial of a multi-modal exercise intervention in Huntington’s disease. Parkinsonism Relat Disord. 2016;31:46–52.CrossRefPubMed
21.
go back to reference Exuzides A, Matos JE, Patel AM, Martin AA, Ricker B, Bega D. Understanding the burdens associated with Huntington’s disease in manifest patients and care partners–comparing to Parkinson’s disease and the general population. Brain Sci. 2022;12(2):161.CrossRefPubMedPubMedCentral Exuzides A, Matos JE, Patel AM, Martin AA, Ricker B, Bega D. Understanding the burdens associated with Huntington’s disease in manifest patients and care partners–comparing to Parkinson’s disease and the general population. Brain Sci. 2022;12(2):161.CrossRefPubMedPubMedCentral
22.
go back to reference Shaw E, Mayer M, Ekwaru P et al. Disease burden of Huntington’s disease (HD) on people living with HD and care partners in Canada. J Huntingtons Dis. 2022(Preprint):1–15. Shaw E, Mayer M, Ekwaru P et al. Disease burden of Huntington’s disease (HD) on people living with HD and care partners in Canada. J Huntingtons Dis. 2022(Preprint):1–15.
23.
go back to reference Hawton A, Green C, Goodwin E, Harrower T. Health state utility values (QALY weights) for Huntington’s disease: an analysis of data from the European Huntington’s disease network (EHDN). Eur J Health Econ. 2019;20:1335–47.CrossRefPubMedPubMedCentral Hawton A, Green C, Goodwin E, Harrower T. Health state utility values (QALY weights) for Huntington’s disease: an analysis of data from the European Huntington’s disease network (EHDN). Eur J Health Econ. 2019;20:1335–47.CrossRefPubMedPubMedCentral
24.
go back to reference Roos RAC. Huntington’s disease: a clinical review. Orphanet J Rare Dis. 2010;5(1):40. Roos RAC. Huntington’s disease: a clinical review. Orphanet J Rare Dis. 2010;5(1):40.
25.
go back to reference Calvert M, Pall H, Hoppitt T, Eaton B, Savill E, Sackley C. Health-related quality of life and supportive care in patients with rare long-term neurological conditions. Qual Life Res. 2013;22:1231–8.CrossRefPubMed Calvert M, Pall H, Hoppitt T, Eaton B, Savill E, Sackley C. Health-related quality of life and supportive care in patients with rare long-term neurological conditions. Qual Life Res. 2013;22:1231–8.CrossRefPubMed
26.
go back to reference Hocaoglu M, Gaffan EA, Ho AK. The Huntington’s Disease health-related quality of life questionnaire (HDQoL): a disease‐specific measure of health‐related quality of life. Clin Genet. 2012;81(2):117–22.CrossRefPubMedPubMedCentral Hocaoglu M, Gaffan EA, Ho AK. The Huntington’s Disease health-related quality of life questionnaire (HDQoL): a disease‐specific measure of health‐related quality of life. Clin Genet. 2012;81(2):117–22.CrossRefPubMedPubMedCentral
27.
go back to reference Carlozzi NE, Victorson D, Sung V, et al. HD-PRO-TRIAD™ validation: A patient-reported instrument for the symptom triad of Huntington’s Disease. Tremor Other Hyperkinet Mov (N Y). 2014;4. Carlozzi NE, Victorson D, Sung V, et al. HD-PRO-TRIAD™ validation: A patient-reported instrument for the symptom triad of Huntington’s Disease. Tremor Other Hyperkinet Mov (N Y). 2014;4.
28.
go back to reference Wild EJ, Tabrizi SJ, Wood N. Huntington’s disease. Neurogenetics: A Guide for Clinicians Cambridge. Cambridge University Press; 2012. pp. 64–82. Wild EJ, Tabrizi SJ, Wood N. Huntington’s disease. Neurogenetics: A Guide for Clinicians Cambridge. Cambridge University Press; 2012. pp. 64–82.
29.
go back to reference Rowen D, Brazier J, Roberts J. Mapping SF-36 onto the EQ-5D index: how reliable is the relationship? Health Qual Life Outcomes. 2009;7(1):1–9.CrossRef Rowen D, Brazier J, Roberts J. Mapping SF-36 onto the EQ-5D index: how reliable is the relationship? Health Qual Life Outcomes. 2009;7(1):1–9.CrossRef
30.
go back to reference Billet J, Levine A, Johannesen J, et al. Patient experiences in early Huntington’s disease-qualitative research to inform development of a patient-reported instrument of everyday functioning (P3-11.003). AAN Enterprises; 2022. Billet J, Levine A, Johannesen J, et al. Patient experiences in early Huntington’s disease-qualitative research to inform development of a patient-reported instrument of everyday functioning (P3-11.003). AAN Enterprises; 2022.
31.
go back to reference Petrillo J, Sawant R, Lee A et al. Cognitive Performance and self-reported functioning in Huntington’s disease: results from a real-world study. Presented at the CHDI Foundation 2023 Huntington’s Disease Therapeutics Conference; 2023. Dubrovnik, Croatia. Petrillo J, Sawant R, Lee A et al. Cognitive Performance and self-reported functioning in Huntington’s disease: results from a real-world study. Presented at the CHDI Foundation 2023 Huntington’s Disease Therapeutics Conference; 2023. Dubrovnik, Croatia.
32.
go back to reference Watkins K, Purks J, Kumar A, Sokas RK, Heller H, Anderson KE. Huntington’s disease and employment: the relative contributions of cognitive and motor decline to the decision to leave work. J Huntington’s Disease. 2018;7(4):367–77.CrossRef Watkins K, Purks J, Kumar A, Sokas RK, Heller H, Anderson KE. Huntington’s disease and employment: the relative contributions of cognitive and motor decline to the decision to leave work. J Huntington’s Disease. 2018;7(4):367–77.CrossRef
33.
go back to reference Wolowacz SE, Briggs A, Belozeroff V, et al. Estimating health-state utility for economic models in clinical studies: an ISPOR good research practices task force report. Value Health. 2016;19(6):704–19.CrossRefPubMed Wolowacz SE, Briggs A, Belozeroff V, et al. Estimating health-state utility for economic models in clinical studies: an ISPOR good research practices task force report. Value Health. 2016;19(6):704–19.CrossRefPubMed
34.
go back to reference Boileau NR, Stout JC, Paulsen JS, et al. Reliability and validity of the HD-PRO-Triad TM, a health-related quality of life measure designed to assess the symptom triad of Huntington’s disease. J Huntingtons Dis. 2017;6(3):201–15.CrossRefPubMedPubMedCentral Boileau NR, Stout JC, Paulsen JS, et al. Reliability and validity of the HD-PRO-Triad TM, a health-related quality of life measure designed to assess the symptom triad of Huntington’s disease. J Huntingtons Dis. 2017;6(3):201–15.CrossRefPubMedPubMedCentral
35.
go back to reference Geraerds AJ, Polinder S, Spronk I, et al. Sensitivity of the EQ-5D-5L for fatigue and cognitive problems and their added value in Q-fever patients. Qual Life Res. 2022;31(7):2083–92.CrossRefPubMedPubMedCentral Geraerds AJ, Polinder S, Spronk I, et al. Sensitivity of the EQ-5D-5L for fatigue and cognitive problems and their added value in Q-fever patients. Qual Life Res. 2022;31(7):2083–92.CrossRefPubMedPubMedCentral
36.
go back to reference de Graaf JA, Kuijpers MM, Visser-Meily JM, Kappelle LJ, Post MW. Validity of an enhanced EQ-5D-5L measure with an added cognitive dimension in patients with stroke. Clin Rehabil. 2020;34(4):545–50.CrossRefPubMed de Graaf JA, Kuijpers MM, Visser-Meily JM, Kappelle LJ, Post MW. Validity of an enhanced EQ-5D-5L measure with an added cognitive dimension in patients with stroke. Clin Rehabil. 2020;34(4):545–50.CrossRefPubMed
37.
go back to reference Keetharuth AD, Hussain H, Rowen D, Wailoo A. Assessing the psychometric performance of EQ-5D-5L in dementia: a systematic review. Health Qual Life Outcomes. 2022;20(1):139.CrossRefPubMedPubMedCentral Keetharuth AD, Hussain H, Rowen D, Wailoo A. Assessing the psychometric performance of EQ-5D-5L in dementia: a systematic review. Health Qual Life Outcomes. 2022;20(1):139.CrossRefPubMedPubMedCentral
38.
go back to reference Mcgrath C, Rofail D, Gargon E, Abetz L. Using qualitative methods to inform the trade-off between content validity and consistency in utility assessment: the example of type 2 diabetes and Alzheimer’s disease. Health Qual Life Outcomes. 2010;8(1):1–13.CrossRef Mcgrath C, Rofail D, Gargon E, Abetz L. Using qualitative methods to inform the trade-off between content validity and consistency in utility assessment: the example of type 2 diabetes and Alzheimer’s disease. Health Qual Life Outcomes. 2010;8(1):1–13.CrossRef
39.
go back to reference Finch AP, Brazier J, Mukuria C. Selecting bolt-on dimensions for the EQ-5D: testing the impact of hearing, sleep, cognition, energy, and relationships on preferences using pairwise choices. Med Decis Mak. 2021;41(1):89–99.CrossRef Finch AP, Brazier J, Mukuria C. Selecting bolt-on dimensions for the EQ-5D: testing the impact of hearing, sleep, cognition, energy, and relationships on preferences using pairwise choices. Med Decis Mak. 2021;41(1):89–99.CrossRef
40.
go back to reference Krabbe PF, Stouthard ME, Essink-Bot M-L, Bonsel GJ. The effect of adding a cognitive dimension to the EuroQol multiattribute health-status classification system. J Clin Epidemiol. 1999;52(4):293–301.CrossRefPubMed Krabbe PF, Stouthard ME, Essink-Bot M-L, Bonsel GJ. The effect of adding a cognitive dimension to the EuroQol multiattribute health-status classification system. J Clin Epidemiol. 1999;52(4):293–301.CrossRefPubMed
41.
go back to reference Sun Z, Ghosh S, Li Y, et al. A probabilistic disease progression modeling approach and its application to integrated Huntington’s disease observational data. JAMIA Open. 2019;2(1):123–30.CrossRefPubMedPubMedCentral Sun Z, Ghosh S, Li Y, et al. A probabilistic disease progression modeling approach and its application to integrated Huntington’s disease observational data. JAMIA Open. 2019;2(1):123–30.CrossRefPubMedPubMedCentral
43.
go back to reference Rowen D, Brazier J, Ara R, Azzabi Zouraq I. The role of condition-specific preference-based measures in health technology assessment. PharmacoEconomics. 2017;35:33–41.CrossRefPubMed Rowen D, Brazier J, Ara R, Azzabi Zouraq I. The role of condition-specific preference-based measures in health technology assessment. PharmacoEconomics. 2017;35:33–41.CrossRefPubMed
46.
go back to reference Brazier J, Peasgood T, Mukuria C et al. The EQ health and wellbeing: overview of the development of a measure of health and wellbeing and key results. Value Health. 2022. Brazier J, Peasgood T, Mukuria C et al. The EQ health and wellbeing: overview of the development of a measure of health and wellbeing and key results. Value Health. 2022.
47.
go back to reference Claassen DO, Goldschmidt D, Zhou M, Leo S, Ribalov R, Ayyagari R. Defining utility values for chorea health states in patients with Huntington’s disease (4360). Neurology. 2021;96(15 Supplement):4360.CrossRef Claassen DO, Goldschmidt D, Zhou M, Leo S, Ribalov R, Ayyagari R. Defining utility values for chorea health states in patients with Huntington’s disease (4360). Neurology. 2021;96(15 Supplement):4360.CrossRef
48.
go back to reference Rodriguez Santana I, Frank S, Fisher A, et al. POSB348 Differences in the health-related quality of life of Huntington’s disease patients by disease stage in the US and EU5 from the Huntington’s Disease Burden of Illness Study (HDBOI). Presented at the Value Health; 2022. Rodriguez Santana I, Frank S, Fisher A, et al. POSB348 Differences in the health-related quality of life of Huntington’s disease patients by disease stage in the US and EU5 from the Huntington’s Disease Burden of Illness Study (HDBOI). Presented at the Value Health; 2022.
49.
go back to reference Fryback DG, Dunham NC, Palta M, et al. US norms for six generic health-related quality-of-life indexes from the national health measurement study. Med Care. 2007;45(12):1162.CrossRefPubMedPubMedCentral Fryback DG, Dunham NC, Palta M, et al. US norms for six generic health-related quality-of-life indexes from the national health measurement study. Med Care. 2007;45(12):1162.CrossRefPubMedPubMedCentral
Metadata
Title
Health state utility estimates for value assessments of novel treatments in Huntington’s disease: a systematic literature review
Authors
Ruta Sawant
Kyle Paret
Jennifer Petrillo
Aaron Koenig
Sorrel Wolowacz
Naoko Ronquest
Hugh Rickards
Publication date
01-12-2024
Publisher
BioMed Central
Published in
Health and Quality of Life Outcomes / Issue 1/2024
Electronic ISSN: 1477-7525
DOI
https://doi.org/10.1186/s12955-024-02242-1

Other articles of this Issue 1/2024

Health and Quality of Life Outcomes 1/2024 Go to the issue